Expression microarray analysis identified over 930 genes regulated during puberty in the mouse mammary gland. Most prominent were genes whose expression increased in parallel with pubertal development and remained high thereafter. Members of the Wnt, transforming growth factor-b and oestrogen-signalling pathways were significantly overrepresented. Comparison to expression data from CITED1 knockout mice identified a subset of oestrogen-responsive genes displaying altered expression in the absence of CITED1. Included in this subset are stanniocalcin2 (Stc2) and amphiregulin (Areg). Chromatin immunoprecipitation revealed that ERa binds to oestrogen response elements in both the Stc2 and Areg genes in the mammary gland during puberty. Additionally, CITED1 and ERa localize to the same epithelial cells of the pubertal mammary gland, supporting a role for interaction of these two proteins during normal development. In a human breast cancer data set, expression of Stc2, Areg and CITED1 parallel that of ERa. Similar to ERa, CITED1 expression correlates with good outcome in breast cancer, implying that potential maintenance of the ERa-CITED1 co-regulated signalling pathway in breast tumours can indicate good prognosis.
Introduction
Pubertal mammary gland development is a naturally occurring period of rapid, highly controlled growth. In response to hormones, puberty sees the formation of a mature gland through ductal morphogenesis and invasion of the fat pad by an expanding system of branched epithelial ducts. At the tip of the growing ducts are terminal end bud (TEB) structures. In the mouse, 'a remarkable rate of ductal elongation of about 0.5 mm/ day' can be observed when TEBs are present (Daniel and Silberstein, 2000) . TEBs are a unique feature and a driving force of pubertal ductal morphogenesis. TEBs consist of a single outer layer of undifferentiated cells known as cap cells and multiple inner layers of body cells. The cap cells are considered to be the pleuripotential stem cells of the developing gland (Williams and Daniel, 1983) . The cap cell layer is continuous with the myoepithelium of the subtending duct (Williams and Daniel, 1983) . The body cells closest to the cap cell layer are highly proliferative, support outward growth of the duct and give rise to epithelial cells of the mature duct. The body cells furthest from the cap cell layer undergo apoptosis, an important feature facilitating formation of the ductal lumen (Humphreys et al., 1996) . TEBs regress when epithelial ducts reach the edges of the fat pad and are absent from the mature adult gland.
The functional purpose of pubertal mammary gland development is to prepare the gland for subsequent growth and differentiation during pregnancy. In the absence of a subsequent pregnancy, the nulliparous gland is left more susceptible to cancer than a parous gland (Russo et al., 2005) . It is thought that the nulliparous gland, with its lack of differentiation, has a greater proportion of undifferentiated stem cells than the gland at any other time, which may account for later transformation (Ball, 1998; Russo et al., 2005) . We therefore hypothesize that the mechanisms of development employed during puberty, which are required to reach the adult state, may have relevance for cancer susceptibility and/or tumour progression.
Expression microarray analysis of developmental time courses is an effective way of identifying key molecular players. To date, any such mammary gland analyses have mostly focussed on later stages of development (pregnancy, lactation, involution) Master et al., 2002; Gass et al., 2003; Rudolph et al., 2003; Clarkson et al., 2004; Stein et al., 2004) . Here we present an expression microarray time course analysis covering five stages of pubertal development, from the appearance to the regression of TEBs. We highlight members of the Wnt, transforming growth factor-b (TGFb) and oestrogen signalling pathways, which potentially contribute to mammary gland development at this time. We compare our findings from normal development with those of altered pubertal development in the CITED1 knockout (KO) mouse. Our results implicate CITED1 as a co-regulator of oestrogen signalling during puberty and suggest that such signalling pathways are maintained in a subgroup of breast tumours in women exhibiting good prognosis.
Results

Expression microarray analysis of pubertal mammary gland development
To assess the timing of pubertal mammary gland development, we prepared wholemounts from 3-to 7-week-old mice. We consistently found (n ¼ 36 mice examined) that TEBs were absent at 3 weeks, present at 4, 5 and 6 weeks and had regressed by 7 weeks. Representative wholemounts are shown in Figure 1a . Based on the wholemount analysis, these five time points (3, 4, 5, 6 and 7 weeks) were chosen for subsequent microarray analysis. The aim of the study was to assess gene expression changes associated with mammary gland development that accompanies the onset of puberty, that is that which reflects: (1) the advancement of the mammary tree through the fat pad and (2) the appearance to the disappearance of TEBs. Our wholemount analysis showed that using mammary glands from age-matched mice of 3-7 weeks would cover this activity. The disadvantage of our design is that mice in our later time points might be at different stages of the oestrus cycle and so exhibit heterogeneous gene expression. However, by sample pooling and integration of independent replicate pools, we derived 'representative' gene expression profiles that were unique to each time point and significantly different from all others (see Figure 1b , hierarchical clustering condition tree).
A total of 14 samples were hybridized to Affymetrix MOE430A arrays (each time point in triplicate except for 5 weeks which was in duplicate). Quality control hierarchical clustering of the 14 arrays, based on the expression of all 22 000 transcripts, clustered samples from the same time point together with the exception of one of the 4 week samples, which was only slightly misplaced ( Figure 1b , condition tree). This confirmed that age was a prominent driver of gene expression. We have already seen that age reflects pubertal mammary gland development and ductal morphogenesis ( Figure 1a) . The cluster analysis also indicated that the expression profiles of 3 and 4 week samples were quite similar and distinct from those of 5, 6 and 7 week samples ( Figure 1b , condition tree).
A master list ('pubertal genes') of 1126 probe sets representing 930 unique genes was identified, from which subsequent analysis was performed (Supplementary Data 1). Each of the pubertal genes was either upregulated or downregulated by at least twofold during pubertal mammary gland development (Figure 1b , gene tree). A trend was evident for genes to increase in expression from 3 and 4 weeks to 5, 6 and 7 weeks (Figure 1b , transition from blue to red). OntoExpress (Draghici et al., 2003) highlighted the following biological functions as being more prevalent than expected among the pubertal genes: growth factor activity, cell growth (cell proliferation and cell cycle genes), Wnt receptor signalling, metabolism (in particular fatty acid metabolism, proteolysis and peptidolysis) and catalysis (acyltransferase and oxidoreductase activity).
As an indication of data quality, the expression profiles of known mediators of pubertal mammary gland development were examined. Pubertal ductal morphogenetic dysfunction has been observed in mouse models with inhibition of amphiregulin (Areg), inhibinbb (Inhbb), matrix metalloproteinases (Mmp2, Mmp3), E-cadherin (Cdh1), the transporter, Slc12a2 and prolactin receptor (Prlr) expression (Howlin et al., 2006a) . Expression of all of these genes was found to increase in our data set ( Figure 1c) . Similarly, KO mice have shown that CITED1, possibly through regulation of oestrogen signalling, is a mediator of pubertal ductal outgrowth and our data confirmed the increase in expression of CITED1 during normal pubertal mammary gland development (Figure 1c; and Howlin et al., 2006b ).
Comparison to parity-related gene expression changes After puberty, in the absence of a subsequent pregnancy, the adult nulliparous gland retains a higher susceptibility to cancer than an age-matched parous gland . A parity-associated signature of genes, that are either upregulated or downregulated in the age-matched parous versus nulliparous gland, has been identified and may be responsible for the differences in cancer susceptibility . We used a method of unsupervised hierarchical clustering to group the 14 pubertal arrays based only on the expression of the 36 genes in the parity-associated gene signature. Significant differences in expression were seen, and these 36 genes alone were sufficient to cluster the arrays accurately by time point (Figure 1d ). Such a clustering pattern was not seen using a group of 36 random genes (data not shown). The majority of genes that change with parity are initially upregulated during puberty between 4 and 5 weeks of age (Figure 1d ).
'TEB profile' genes Genes that were expressed or repressed specifically when TEBs were present were termed 'TEB profile' genes. That is, genes that were upregulated between 3 and 4 weeks and downregulated between 6 and 7 weeks (expressed when TEBs are present) and genes that were downregulated between 3 and 4 weeks and upregulated between 6 and 7 weeks (repressed when TEBs are present). We identified 15 expressed and 9 repressed 'TEB profile' genes ( Figure 2 3 3 3 4 4 4 5 5 6 6 6 7 7 7 3 4 3 3 4 4 5 5 6 6 6 7 7 7
Parity-associated genes 3 3 3 4 4 4 5 5 6 6 6 7 7 7 regulation as overrepresented functions with more than half of the genes belonging to these categories ( Figure 2 ). This is in strong agreement with findings of Morris et al. (2006) who studied genes specifically expressed in TEBs relative to ductal tissue and found that 57% of TEBspecific genes had roles in cell cycle regulation, DNA replication or cell division (Morris et al., 2006) . TEBs are also known to possess the highest levels of programmed cell death relative to all other stages of mammary gland development (Humphreys et al., 1996) . Individually, several of the 'TEB profile' genes have previously been associated with pubertal mammary gland development, including gelsolin, igfbp2 and members of the Ets family of transcription factors (Crowley et al., 2000; Allar and Wood, 2004; Galang et al., 2004 The normalized expression levels of nine genes decreased by X1.5-fold between 3 and 4 weeks and increased by X1.5-fold between 6 and 7 weeks. X axis: time points (weeks), y axis: log-relative expression. (B) Table listing the 15 expressed and 9 repressed 'TEB profile' genes. Genes with known roles in apoptosis or cell cycle regulation are noted.
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Comparison of the pubertal genes to a database of TGFb-responsive genes (http://actin.ucd.ie/tgfbeta) identified 286 TGFb-responsive genes with changing expression profiles during pubertal mammary gland development (Supplementary Data 3). The frequency of TGFb-responsive genes among the pubertal genes is significantly higher than would be expected in a random group of genes of this size (Po0.0001) and implies the potential importance of TGFb signalling during pubertal mammary gland development.
Most prominently, comparison of the pubertal genes to a database of oestrogen-responsive genes (Tang et al., 2004) identified 122 oestrogen-responsive genes with changing expression profiles during pubertal mammary ERa-CITED1 pathway in breast tumours J McBryan et al gland development (Table 1 ). The apparent change in the expression level of this number of oestrogenresponsive genes in the total cohort of genes that changed is significantly greater than that expected by chance (P ¼ 0.0035) ( Figure 3a) . As the post-pubertal time point samples were pools and not selected for stage of the oestrus cycle, this may not accurately represent, but only estimate, the actual number of oestrogenresponsive genes that are upregulated in the mammary gland over this period. The expression profiles of eight of these oestrogen-responsive pubertal genes were confirmed by real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis (Figure 3b ). Sequence analysis of two of the gene sequences, stanniocalcin2 (Stc2) and Areg, identified one putative oestrogen-response element (ERE) downstream of the transcription start site in both of these genes (Figure 3c ). Chromatin immunoprecipitation (ChIP) analysis demonstrated that an anti-ERa antibody successfully precipitated the regions of DNA containing these EREs in 6-week mammary glands (Figure 3c ). The specificity of the antibody binding to this region was confirmed by amplification of an independent region of the Stc2 promoter that does not contain an ERE (Figure 3c , control). Thus, the oestrogen responsiveness of Stc2 and Areg during puberty is most likely regulated by direct ERa binding to specific EREs in these genes. The Wnt, TGFb and oestrogen-signalling pathways are all known targets for transcriptional co-regulation by CITED1 (Yahata et al., 2001; Plisov et al., 2005) . We have previously identified gene expression changes associated with the loss of CITED1 by comparing expression levels between 6-week CITED1 KO and control mammary glands (Howlin et al., 2006b) . Cross comparison of the data sets identified several members of the Wnt, TGFb and oestrogen-signalling pathways, which have altered expression levels in CITED1 KO mice relative to controls (Supplementary Data 2, 3 and Table 1 ). CITED1 KO mice display reduced ductal outgrowth, altered branch patterning and a reduced number of TEBs during puberty ( Figure 4A ; Howlin et al., 2006b) . The comparative gene expression data therefore support the building evidence for an important role for Wnt, TGFb and oestrogen signalling in normal pubertal mammary gland development as well as a potential role for CITED1 in regulating these pathways.
Co-regulation of pubertal gene expression by ERa and CITED1
To consider the potential involvement of CITED1 solely in modulating oestrogen signalling in the pubertal mammary gland, we compared the cellular localization of CITED1 and ERa. Both proteins, in agreement with previous reports, were expressed in some but not all epithelial cells of the ducts in an on/off pattern (Zeps et al., 1998; Howlin et al., 2006b) . ERa appeared nuclear, while CITED1 was predominantly cytoplasmic and weakly nuclear. Interestingly, both proteins were expressed in exactly the same ductal cells and absent from the same cells (Figure 4Ba ). Supplementary Data 4 show immunofluorescence images in xy and yz planes to support the 2D confocal images shown in Figure 4Ba . Nuclear colocalization of ERa and CITED1 is apparent from these images. This staining pattern provides additional suggestive evidence of an interaction between ERa and CITED1. ERa staining in the CITED1 KO mammary gland appeared comparable with that in the wild-type (wt) gland (Figure 4Bb) .
In wt TEBs, cap cells expressed neither ERa nor CITED1 (Figure 4Bd ). In the body cells, however, both proteins were expressed in an on/off pattern similar to that seen in the ducts. ERa expression appeared to be dispersed throughout the body cells of the TEB. CITED1, however, displayed a gradient of expression with strong expression in the outermost body cells (closest to the cap cell layer) and little or no expression in the inner body cells (closest to the lumen). Thus, ERa and CITED1 localized to the same outermost body cells, but those body cells closest to the lumen expressed ERa with little or no CITED1 (Figure 4Bd) .
The body cells closest to the lumen have been reported to undergo extensive apoptosis (Humphreys et al., 1996) . As these cells express little or no CITED1, we questioned whether the location of apoptotic cells would be altered in CITED1 KO mice, where CITED1 ERa-CITED1 pathway in breast tumours J McBryan et al was absent from all body cells. Immunofluorescence determined that the apoptotic marker, cleaved caspase 3, was located predominantly in the inner body cells of TEBs of the CITED1 KO mice (Figure 4Ca ). The localization and extent of this staining is consistent with previous observations of both cleaved caspase 3 and terminal deoxy transferase uridine triphosphate nick end-labeling staining in TEBs of wt mice (Humphreys et al., 1996; Mailleux et al., 2007) . This would suggest that CITED1 knockout is not associated with gross changes in apoptosis. We observed similar expression patterns of cleaved caspase 3 in the ducts of wt and CITED1 KO mice, where occasional ductal cells displayed nuclear cleaved caspase 3 expression ( Figure  4Cb-c) . Ductal cells undergoing apoptosis tended to be those adjacent to ERa-positive cells and did not express ERa themselves ( Figure 4C ). Thus, the reduced ductal outgrowth and reduced number of TEBs observed in the 6-week-old CITED1 KO mice do not appear to be due to differences in apoptosis between wt and CITED1 KO mice.
To further examine the effect of loss of CITED1 on oestrogen-signalling pathways, the expression of the oestrogen-responsive pubertal genes Stc2 and Areg was Figure 4D ). Expression was compared between 3-and 6-week glands using typical underdeveloped CITED1 KO glands and also particularly well developed CITED1 KO glands (6d), which exhibited a similar extent of ductal outgrowth to the wt.
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For both genes, the increase in expression between 3 and 6 weeks, clearly seen in the wt glands, was either absent or considerably reduced in the CITED1 KO glands. This trend was present despite the stage of development of the KO gland, although it was more pronounced in the less well-developed gland. This observation of disrupted oestrogen signalling in CITED1 KO mice further supports the theory of a co-regulatory interaction between ERa and CITED1.
Relating mouse pubertal development to human cancer progression As ERa expression is associated with outcome of human breast cancer, it became a matter of interest to see if the co-regulatory events observed in pubertal mouse mammary gland development were also observed in human breast tumours. We considered the expression microarray study carried out by van de Vijver et al. (2002) . Expression profiles were derived from the primary tumours of 295 patients, and follow-up information is available for 18.2 years (median: 6.7 years) (van de Vijver et al., 2002) . Dividing the patients into groups based on the expression of CITED1 in these tumours, we found a significant correlation between high CITED1 expression levels and both event-free survival and overall survival (Po0.05 and o0.01, respectively) ( Figure 5a ). The expression of CITED1 correlated positively with the expression of ERa in these tumours (Po0.0001). Additionally, the expression of CITED1 positively correlated with expression of Areg (P ¼ 0.0002), Stc2 (Po0.0001) and Stc1 (Po0.0001) (Figure 5b ). These data suggest that an ERa-CITED1 co-regulated signalling pathway may be maintained in some breast tumours and may be an indicator of good prognosis.
Discussion
We have provided a comprehensive gene expression data set for the period of pubertal mammary gland development from the appearance to the regression of TEBs.
Our global time course analysis of the entire gland differs from the approach of other research groups who have looked at a single pubertal time point and compared isolated segments of the gland (Kouros-Mehr and Werb, 2006; Morris et al., 2006) . While the different approaches complement each other and a degree of overlap was apparent between findings, we identify both key global trends of pubertal development as well as dynamic expression changes for novel genes, not previously associated with pubertal mammary gland development. The 'TEB profile' genes provide a novel list of pubertal genes that also play possible roles in breast cancer progression. Reports have shown high levels of ehf and tnfrsf12a in breast tumours (Galang et al., 2004; Michaelson et al., 2005) . Cdc2a levels are known to increase in response to carcinogen treatment in the virgin mammary gland (Uehara et al., 2006) . Expression of syndecan1 can promote breast carcinoma growth (Maeda et al., 2006) . Igfbp2 can be used as a marker for anti-oestrogen-resistant breast cancer cell lines (JunckerJensen et al., 2006) . Calponin1 can be used to distinguish invasive from non-invasive breast lesions (Werling et al., 2003) . A loss of sfrp1, a Wnt inhibitor, is associated with breast cancer progression and poor prognosis, as is the presence of Ets1 (Klopocki et al., 2004; Lincoln and Bove, 2005) . These findings indicate the potential relationship between understanding the mechanisms of normal developmental programmes and gaining understanding of oncogenic growth.
Accumulating evidence indicates that hyperactive Wnt signalling occurs in association with the development and progression of human breast cancer (Yook et al., 2006) . Wnt signalling pathway members identified here, such as Wnt2, Wnt5a and Fzd1, have previously been observed in the pubertal mammary gland (WeberHall et al., 1994; Kouros-Mehr and Werb, 2006) . Members of the Wnt family are thought to act as paracrine mediators of progesterone signalling during pregnancy but, to date, a clear role has not been established for Wnts during puberty (Brisken et al., 2000) . A number of TGFb-signalling pathway members have also been implicated in the progression of breast cancer. For example, pleiotrophin, a proto-oncogene identified in our study, is expressed at high levels in breast cancer (Zhang et al., 1997) . TGFb is known to be a potent inhibitor of mammary epithelial proliferation and is believed to play an important role in branch patterning during normal pubertal development, ERa (green) displays nuclear staining in some but not all of the ductal epithelial cells in an on/off pattern. CITED1 (red) is predominantly cytoplasmic and weakly nuclear, and is located in some but not all of the ductal epithelial cells in an on/off pattern. Merged image shows that ERa and CITED1 localized to the same ductal cells. In TEBs, ERa is located in body cells but absent from cap cells. CITED1 is located in body cells, particularly the outermost body cells and absent from cap cells. Merged image shows CITED1 and ERa localize to the same outermost body cells. Body cells closest to the lumen express ERa but only weakly express CITED1. (C) Fluorescent microscopy of sections through 6-week glands. (a) CITED1 KO TEB stained for nuclear DAPI (blue), ERa (green) and cleaved caspase 3 (red). Cleaved caspase 3 staining is both nuclear and cytoplasmic and is confined to the inner body cells of the TEB and the presumptive luminal space. (b) Wt duct and (c) CITED1 KO duct, both stained for ERa (green) and cleaved caspase 3 (red). Cleaved caspase 3 was found only in occasional ductal cells. Ductal cells that stained positively for cleaved caspase 3 did not express ERa. Scale bars 10 mm. (D) Expression of oestrogen-responsive pubertal genes, Stc2 and Areg, measured by real-time RT-PCR in 3-and 6-week wt and CITED1 KO glands (n ¼ 3). Exceptionally, well-developed 6-week CITED1 KO glands showing a similar extent of ductal outgrowth as the wt glands were also analysed (6d).
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Many of the genes whose expression levels increase during puberty retain elevated expression levels at the end of puberty. Several of these genes have known roles in pregnancy and/or lactation (e.g. Prlr, casein family members). Thus, this expression trend reflects the role of puberty as a preparatory step for later mammary development and not as an isolated process in itself. This can also be seen by the comparison with parityinduced changes, where many of the genes that are upregulated at puberty are further upregulated with parity (Figure 1d ; D'Cruz et al., 2002) . However, there are also a number of genes whose expression levels remain high at the end of puberty, which are preserved in the mature virgin gland, but which decrease with parity (e.g. Areg, CITED1). It has previously been reported that Areg expression may contribute to abnormal development in the older, mature mammary gland (Herrington et al., 1997) . Owing to the growth promoting effects exhibited by both Areg and CITED1 (Howlin et al., 2006b) , it is conceivable that the high level of expression of these genes may contribute to the increased susceptibility of the nulliparous gland to cancer (Kenney et al., 1996; D'Cruz et al., 2002; Howlin et al., 2006b) .
The growth promoting effects of CITED1 may be mediated through modulation of oestrogen signalling as oestrogen is known to promote proliferation in the pubertal mouse mammary gland (Zeps et al., 1998) . The localization of CITED1 and ERa to exactly the same epithelial cells of the pubertal mammary gland lends credence to the possibility of an interaction between these two proteins. Similarly, the downregulation of oestrogen-responsive genes in CITED1 KO mice implies that CITED1 does modulate oestrogen-signalling pathways. The mechanism by which CITED1 and ERa may interact in the pubertal mammary gland remains unclear. The predominantly cytoplasmic location of CITED1 may be a result of exportin 1 (CRM-1)-dependent nuclear export, but does not exclude the possibility of an interaction between CITED1 and ERa in the nucleus (Shi et al., 2006) . Indeed, CITED1 has previously been shown to act as a co-activator of oestrogen-dependent transcription by binding directly to ERa, in an oestrogen-dependent manner (Yahata et al., 2001) . The transcriptional activity of CITED1 has also been shown to be regulated by alterations in the phosphorylation status of CITED1 (Shi et al., 2006) . Phosphorylation of CITED1 interferes with p300 binding (Shi et al., 2006) . However, as p300 and ERa appear to interact with different regions of CITED1, it is not yet clear whether phosphorylation of CITED1 affects CITED1-ERa-binding ability (Yahata et al., 2001) .
The potential interaction between CITED1 and ERa is limited to some of the body cells of the TEB. CITED1 expression appears to be lost from the inner body cells, closest to the lumen. We have not examined the mechanisms of CITED1 loss but have only considered the potential consequences of this expression pattern. Inner and outer body cells undergo varying levels of proliferation and apoptosis with proliferation tending to localize to the outer body cells (Humphreys et al., 1996) . It has been shown, in both mouse and human tissue, that proliferating cells tend to be those adjacent to ERa-positive cells (Clarke et al., 1997; Zeps et al., 1998) . As ERa-positive cells are distributed throughout the body cells of the TEB, we speculate that CITED1 may be involved in co-regulating the oestrogen-induced proliferation of the outer body cells and may contribute to the differences in proliferation rate seen between this latter cell type and inner body cells. The role of CITED1 as an indicator of good prognosis in breast cancer may appear to contradict the role of CITED1 as a promoter of pubertal growth. However, this observation is mirrored in the case of ERa, which also promotes pubertal growth and acts as an indicator of good prognosis in breast tumours. CITED1 expression in breast tumours correlated with expression of ERa and also those of Areg and Stc2. This suggests that tumours, in which pathways relevant to normal mammary physiology and development are maintained, may have a significantly better patient outcome than those tumours in which these pathways have been lost. This observation is consistent with the well-established correlation between low tumour grade (histological similarity to normal breast) and good outcome, and with a recent study showing that breast tumours with gene expression profiles most similar to differentiated mammary acini in culture, have a favourable prognosis (Fournier et al., 2006) . While we have demonstrated a relationship between pathways in development and cancer, it is clear that it is not as straightforward as might be expected. Growth factors promoting developmental invasive behaviour may not be assumed to promote cancerous invasion and may, paradoxically, by their expression in a tumour, indicate maintenance of a more regulated and controlled growth.
In conclusion, expression microarray analysis has highlighted novel genes involved in pubertal mammary gland development with potential relevance to breast cancer susceptibility and progression. Our analysis emphasizes the importance of an ERa-CITED1 coregulated signalling mechanism in puberty and, interestingly, retention of this pathway may be indicative of good prognosis in human breast cancer.
Materials and methods
Animals and tissue isolation CD1 mice were euthanized at various stages of development (3, 4, 5, 6 and 7 weeks of age). CITED1 KO mice were bred and genotyped as described previously (Howlin et al., 2006b) . Fourth inguinal mammary glands were isolated and either snap frozen in liquid nitrogen, fixed in appropriate fixative or used immediately for ChIP analysis. Lymph nodes were removed from glands used for microarray and ChIP analysis. CITED1 KO glands harvested for RNA had contralateral glands fixed as wholemounts to give an indication of the extent of ductal outgrowth.
Wholemount analysis
Glands were fixed and stained in carmine alum as described previously (Howlin et al., 2006b) . TEBs were counted in 10 representative wholemounts from each genotype. Unpaired t-test was used for statistical comparison of the means.
Immunofluorescence
Immunofluorescence was performed essentially as described previously (Howlin et al., 2006b ) Primary antibodies used were: rabbit polyclonal anti-CITED1 1:500 (Li et al., 1998) , mouse monoclonal anti-ERa 1:50 (Novocastra Laboratories, Newcastle upon Tyne, UK) and rabbit monoclonal anticleaved caspase 3 (Cell Signaling Technology, Danvers, MA, USA). DAPI (4,6-diamidino-2-phenylindole dihydrochloride, Sigma, St Louis, MO, USA, 0.0001%) was used as a nuclear counterstain. Images were captured using a fluorescent microscope with Axiovision LE software or a Zeiss LSM 510 UVMETA confocal microscope and Zeiss LSM software.
Microarray hybridization and data analysis Total RNA (6 mg) was used to produce biotinylated cRNA according to the manufacturer's instructions (Affymetrix, High Wycombe, UK). Each sample was prepared from a pool of at least three mice, and a total of 15 samples were prepared (three replicates for each of five time points: 3, 4, 5, 6 and 7 weeks of age). Insufficient cRNA was obtained for one of the 5-week replicates, so this time point was analysed in duplicate. Affymetrix test3 arrays were used to confirm the quality of the labelled cRNA before hybridization to the Affymetrix MOE430A arrays. Raw data were imported into Genespring (version 5.0, Agilent Technologies, Santa Clara, CA, USA) and normalization was performed by per chip normalized to the 50th percentile and per gene normalized to the median. A filtering step was applied to select reliable data (probe sets that were flagged as present in seven of 14 time points), and also changing data (determined by twofold changes in normalized expression intensities between any two time points). Trajectory clustering was performed based on 1.5-fold expression changes between consecutive time points where I is X1.5-fold increase in expression, D is X1.5-fold decrease in expression and F is anything in between. Hierarchical clustering was performed using a Pearson correlation with selected gene groups. The parity-associated gene group was extracted from the published gene signature based on gene symbols . Functional categories were determined based on Gene Ontology categories. P-values were calculated using OntoExpress default settings (hypergeomatric distribution, fdr correction), with P-value o0.05 considered to be significant. TGFb and oestrogen-responsive gene comparisons were made based on gene symbols using the T-REGs database of TGFb-responsive genes (http://actin.ucd.ie/ tgfbeta/) and the ERGDB (Estrogen Responsive Genes Database: http://defiant.i2r.a-star.edu.sg/projects/Ergdb-v2/ index.htm) (Tang et al., 2004) . Statistical significance was calculated by w 2 tests based on the assumption that the Affymetrix chips represented 14 000 mouse genes including all genes in the ERGDB and T-REGs databases. Statistical significance for Kaplan-Meier curves was calculated using the log-rank test. Expression microarray analysis of the CITED1 KO mice has been described previously (Howlin et al., 2006b) . Gene lists were generated based on 1.5-fold expression changes between homozygous null (À/À) and control mice (either wt or heterozygous). The entire puberty data set, which is compliant to the MIAME criteria, is deposited at Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under the series accession number GSE6453.
ChIP analysis
Dragon ERE finder was used to identify putative EREs (Bajic et al., 2003) . A ChIP assay kit (Upstate Biotechnology, Billerica, MA, USA) was used according to the manufacturer's instructions and essentially as we have described previously ERa-CITED1 pathway in breast tumours J McBryan et al (Murtagh et al., 2004) . A detailed protocol is provided as Supplementary Data 5. The primary antibody used was: rabbit polyclonal anti-ERa (SantaCruz TransReagent, 5 ml). Normal rabbit serum (5 ml) was used as a control.
Real-time PCR SYBR Green PCR was performed essentially as described previously (Howlin et al., 2006b) 
